Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Andre De Souza, Fabio A. Tavora, Devalingam Mahalingam, Pamela N. Munster, Howard P. Safran, Wafik S. El-Deiry, Benedito A. Carneiro*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Article number595289
JournalFrontiers in immunology
Volume11
DOIs
StatePublished - Oct 19 2020

Keywords

  • 9-ING-41
  • COVID
  • COVID-19
  • GSK-3 inhibitor
  • GSK-3b inhibitor
  • SARS-CoV21
  • glycogen synthase kinase-3 (GSK-3) inhibitor
  • glycogen synthase kinase-3 (GSK3)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this